title: In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial.
abstract: Adoptive immunotherapy with tumor-infiltrating lymphocytes (TIL) and IL-2 appears to produce dramatic regressions in patients with metastatic melanoma and renal cancer. However, the in vivo mechanism of TIL function is not known. We conducted an UCLA Human Subject Protection Committee, Recombinant DNA Advisory Committee, and FDA-approved clinical trial using genetically-marked TIL to test the hypothesis that these cells have unique, tumor-specific in vivo trafficking patterns. TIL and PBL (as a control effector cell population) were isolated and expanded in parallel in vitro in IL-2-containing medium for 4-6 wk. During the expansion, TIL and PBL were separately transduced with the amphotropic retroviral vectors LNL6 and G1Na. Transduced TIL and PBL were coinfused into patients and their respective numbers measured in tumor, peripheral blood, and normal tissues; integrated provirus could be quantitated and distinguished by DNA PCR. Nine patients were treated (six melanoma, three renal) and received between 4.5 x 10(8) and 1.24 x 10(10) total cells. Both "marked" TIL and PBL could be detected circulating in the peripheral blood, in some patients for up to 99 d after infusion. Marked TIL and/or PBL could be detected in tumor biopsies in six of nine patients as early as day 6 and as late as day 99 after infusion. No convincing pattern of preferential trafficking of TIL vs. PBL to tumor was noted. Moreover, concurrent biopsies of muscle, fat, and skin demonstrated the presence of TIL/PBL in comparable or greater numbers than in tumor in five patients. The results of this double gene marking trial provide interesting insights into the life span and trafficking of adoptively transferred lymphocytes, but do not support the hypothesis that TIL specifically traffic to tumor deposits.
authors.affiliation: Department of Surgery, University of California Los Angeles Medical Center 90095, USA.
authors.forename: J S
authors.initials: JS
authors.lastname: Economou
authors.forename: A S
authors.initials: AS
authors.lastname: Belldegrun
authors.forename: J
authors.initials: J
authors.lastname: Glaspy
authors.forename: E M
authors.initials: EM
authors.lastname: Toloza
authors.forename: R
authors.initials: R
authors.lastname: Figlin
authors.forename: J
authors.initials: J
authors.lastname: Hobbs
authors.forename: N
authors.initials: N
authors.lastname: Meldon
authors.forename: R
authors.initials: R
authors.lastname: Kaboo
authors.forename: C L
authors.initials: CL
authors.lastname: Tso
authors.forename: A
authors.initials: A
authors.lastname: Miller
authors.forename: R
authors.initials: R
authors.lastname: Lau
authors.forename: W
authors.initials: W
authors.lastname: McBride
authors.forename: R C
authors.initials: RC
authors.lastname: Moen
mesh_terms: D000328:Adult; D000368:Aged; D001483:Base Sequence; D002292:Carcinoma, Renal Cell / Q000628:therapy; D017931:DNA Primers / Q000737:chemistry; D005069:Evaluation Studies as Topic; D005260:Female; D005819:Genetic Markers; D005822:Genetic Vectors; D006801:Humans; D007116:Immunization, Passive; D016246:Lymphocytes, Tumor-Infiltrating / Q000166:cytology*; D008297:Male; D008545:Melanoma / Q000628:therapy; D008875:Middle Aged; D008969:Molecular Sequence Data
chemical_list: D017931:DNA Primers; D005819:Genetic Markers